Clinical-stage gene-therapy company Genprex (NASDAQ: GNPX) is at the forefront to advance innovative developments in the war against lung cancers, testing its trademarked Oncoprex immunogene therapy. A recent article discussing this reads, “Oncoprex’s phase I and II clinical-stage trial therapies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, … Continue reading “QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) at Forefront to Advance Innovative Developments in Fight Against Lung Cancers”
Clinical-stage gene therapy company Genprex Inc. (NASDAQ: GNPX) this morning announced that its collaborators from the University of Texas MD Anderson Cancer Center (“MD Anderson”) detailed positive preclinical data, in a poster presented at the American Association of Cancer Research Meeting 2019, regarding the combination of the TUSC2 gene with an anti-PD1 antibody, pembrolizumab, for … Continue reading “QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Collaborators Report Positive Preclinical Data at 2019 AACR Annual Meeting”
Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) on Monday provided a clinical, corporate and financial update for the year ended December 31, 2018. Among other highlights, Genprex reached various milestones in 2018 and early 2019 which included completing its initial public offering (“IPO”) and listing of common stock on NASDAQ Capital Market, completing a $10 … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Posts Clinical, Corporate and Financial Update”
Lung cancer is one of the most prevalent and deadly cancers worldwide. Genprex aims to develop cutting-edge gene therapies to improve outcomes, which have not changed significantly in the past 25 years despite radical advances in drug development and novel therapeutic standards. Genprex holds a portfolio of 30 issued and two pending patents covering technologies … Continue reading “Genprex Inc. (NASDAQ: GNPX) is “One to Watch””
Lung cancer is one of the most commonly occurring tumors in men and women, and it is the common cancer that’s most likely to result in death among all U.S. populations Genprex is advancing its trademarked Oncoprex immunogene therapy as a means of bolstering the body’s protein defenses against lung tumor growth Clinical trials for … Continue reading “Genprex Inc. (NASDAQ: GNPX) Employs Trademarked Gene Therapy in Team-up to Fight Lung Cancer”
Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that it will be presenting at the upcoming ARM Cell & Gene Therapy Investor Day, hosted by the Alliance for Regenerative Medicine, to be held in New York City on March 21, 2019. Unique to the medical and biotech communities, the investor conference focuses on … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) to Present at Seventh Annual ARM Cell & Gene Therapy Investor Day in New York City”
Investment Considerations Genprex is led by a seasoned management team boasting more than 50 years of combined industry experience. The company’s lead product candidate, REQORSA® (quaratusugene ozeplasmid), is being evaluated in multiple clinical trials as a treatment for non-small cell lung cancer and will soon be evaluated in a clinical trial for small cell lung … Continue reading “Genprex Inc. (NASDAQ: GNPX)”
